Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement
- Conditions
- Thrombosis
- Registration Number
- NCT01988766
- Lead Sponsor
- University of Chicago
- Brief Summary
The purpose of this study is to compare the difference in thrombosis as a result of internal jugular (IJ) catheters versus peripherally inserted central catheter (PICC) lines. It is hypothesized that there will be a decreased rate of thrombosis in patients as a result of IJ catheters verses PICC lines.
- Detailed Description
In a cohort of patients from Sept 1, 2010 until December 31, 2011 with chronic kidney disease (CKD) has shown that the incidence of IJ thrombosis after short term catheter access occurred in only 1/26 subjects or 4%. The current study is being done to compare this experience with the incidence of thrombosis from PICC lines. A secondary aim will be to determine if variables such as level of renal function, prior history of thrombosis or atherosclerosis contribute to the risk of thrombosis when PICC lines are placed. This data will provide the first comparison of the incidence of thrombotic complications from short term IJ catheter access versus PICC lines.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1424
- subjects who had a PICC line placed at the University of Chicago between September 1, 2010 and December 31, 2011
- subjects under the age of 18
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of Thrombosis 15 months To calculate the incidence of deep venous thrombosis from PICC lines in patients
- Secondary Outcome Measures
Name Time Method Demographic Risk Factor Association with Risk of Thrombosis from PICC or IJ access 15 months To evaluate if factors, known to be associated with thrombosis and atherosclerosis, are associated with the risk of thrombosis from PICC or IJ access. These factors include: renal failure, diabetes, hypertension, cancer, transplant, gender, age or the indication for the access, including antibiotics or chemotherapy.
Trial Locations
- Locations (1)
The University of Chicago
🇺🇸Chicago, Illinois, United States